Trials / Completed
CompletedNCT04061252
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
A Phase 3, Placebo-Controlled, Double-Blind Comparative Study of KHK4827 With an Open-Label Extension in Subjects With Palmoplantar Pustulosis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK4827 | brodalumab 210mg Q2W, SC |
| DRUG | Placebo | Q2W, SC |
Timeline
- Start date
- 2019-08-10
- Primary completion
- 2021-08-11
- Completion
- 2022-08-05
- First posted
- 2019-08-19
- Last updated
- 2023-02-14
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04061252. Inclusion in this directory is not an endorsement.